Listed by the USPTO as DONOHUE, SEAN R
Tech Center 3700 • Art Units: 1618 3797
This examiner grants 41% of resolved cases
DONOHUE, SEAN R works in tech center 3700 and art unit 1618. The record contains 736 resolved cases, a 41.4% allowance rate, and a median of 1214 days to allowance. The 21.0% interview lift indicates that interviews may support outcomes, but the allowance rate points to the need for rigorous written prosecution and careful claim positioning.
The leading companies are The University of North Carolina at Chapel Hill, Columbia University, and Curium US LLC. The leading firms are AMSTER, ROTHSTEIN & EBENSTEIN LLP, Meunier Carlin & Curfman LLC, and PABST PATENT GROUP LLP. Counsel can use the recurring participants to inform preparation for this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | Final Rejection | Novartis AG |
| 17997299 | METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS | Final Rejection | Novartis AG |
| 18285413 | BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17705781 | Multi-Enzyme Nanoparticle-Assisted Stable Isotope Incorporation Into Small Molecules by Channeling | Final Rejection | The Government of the United States of America, as represented by the Secretary of the Navy |
| 17550542 | BIOMIMETIC ANISOTROPIC POLYMERIC PARTICLES WITH NATURALLY DERIVED CELL MEMBRANES FOR ENHANCED DRUG DELIVERY | Non-Final OA | The Johns Hopkins University |
| 17919848 | Fluorinated Derivatives of Gabapentin and Methods of Use Thereof | Non-Final OA | The General Hospital Corporation |
| 18554403 | COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18247427 | METHODS AND COMPOSITIONS FOR SYNERGISTIC UPTAKE AND RETENTION OF SMALL MOLECULE LIGANDS | Final Rejection | CORNELL UNIVERSITY |
| 18029596 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | Final Rejection | CORNELL UNIVERSITY |
| 18603721 | COMPOUNDS AND COMPOSITIONS USEFUL AS RADIOTRACERS FOR IMAGING OF REACTIVE OXIDATIVE SPECIES | Final Rejection | Wake Forest University Health Sciences |
| 18398557 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION | Final Rejection | NOVOCURE GMBH |
| 18123236 | Small Molecule Ligand-Drug Conjugates for Targeted Cancer Therapy | Non-Final OA | Georgia State University Research Foundation, Inc. |
| 18044356 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA USING VENETOCLAX IN CONJUNCTION WITH LINTUZUMAB-AC225 | Final Rejection | ACTINIUM PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy41.4% of resolved applications examined by Sean R Donohue were allowed (736 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +21.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sean R Donohue took 1,214 days on average from filing to allowance.
Sean R Donohue examines applications in Art Unit 1618 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
